SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
收盘时
US$19.68
−US$0.42 · -2.09%
盘后
US$19.68
US$0.00 · 0.00%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
日内区间
当前US$19.68
52周区间
当前US$19.68
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
99
深度低估
情绪
49
多空交织
风险
38
中等风险
动量
58
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
日内区间
当前US$19.68
52周区间
当前US$19.68
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.01亿 USD | 1.67亿 USD | 1.39亿 USD | 1.06亿 USD | 9015.2万 USD |
| 销货成本 | 4104.7万 USD | 3505.7万 USD | 2946.6万 USD | 1570.5万 USD | 1042.8万 USD |
| 毛利 | 1.6亿 USD | 1.32亿 USD | 1.09亿 USD | 9070.4万 USD | 7972.4万 USD |
| 研究与开发 | 1744.8万 USD | 1656万 USD | 1502.8万 USD | 1362.7万 USD | 1244.1万 USD |
| 销售、一般及管理费用 | 1.65亿 USD | 1.51亿 USD | 1.41亿 USD | 1.37亿 USD | 1.19亿 USD |
| 营业费用 | 1.82亿 USD | 1.67亿 USD | 1.56亿 USD | 1.5亿 USD | 1.31亿 USD |
| 利息收入 | 607.3万 USD | 784.8万 USD | 691.6万 USD | 130.4万 USD | 18.6万 USD |
| 利息支出 | 528.3万 USD | 344万 USD | 346.2万 USD | 281.9万 USD | 536.5万 USD |
| 折旧和摊销 | 271.9万 USD | 437.9万 USD | 542.8万 USD | 345.2万 USD | 208.6万 USD |
| 营业利润 | −2233万 USD | −3524.8万 USD | −4693.1万 USD | −5960.9万 USD | −5167万 USD |
| 净利润 | −1890.8万 USD | −3091.3万 USD | −4333.6万 USD | −6125.6万 USD | −5657.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$23.00
上涨空间 16.87%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2543.07万0.00%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM2262.3万0.03%787.4亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF881.19万0.01%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO810.31万0.06%139.17亿 USD0.24%US$351.1-0.74%
Dimensional - US Small Cap ETFDFAS562.85万0.02%338.04亿 USD0.31%US$78.33+0.20%
Schwab U.S. Small-Cap ETFSCHA481.73万0.02%217.13亿 USD0.03%US$32.56-0.31%
Vanguard Russell 2000 ETFVTWO480.57万0.03%180亿 USD0.06%US$111.77-0.45%
iShares U.S. Medical Devices ETFIHI445.7万0.12%35.74亿 USD0.37%US$52.69-0.19%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Dimensional - US Small Cap ETFDFAS
Schwab U.S. Small-Cap ETFSCHA
Vanguard Russell 2000 ETFVTWO
iShares U.S. Medical Devices ETFIHIAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。